EULAV Asset Management’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-245,000
Closed -$23M 319
2019
Q1
$23M Sell
245,000
-98,000
-29% -$8.57M 0.95% 31
2018
Q4
$22M Buy
343,000
+43,000
+14% +$3.17M 1.1% 22
2018
Q3
$26.8M Buy
300,000
+16,000
+6% +$1.41M 1.15% 24
2018
Q2
$22.6M Buy
284,000
+43,000
+18% +$3.57M 1.04% 25
2018
Q1
$21.5M Buy
241,000
+34,000
+16% +$3.26M 1.03% 22
2017
Q4
$21.6M Buy
207,000
+29,000
+16% +$3.27M 1.02% 23
2017
Q3
$26M Sell
178,000
-1,000
-0.6% -$136K 1.23% 13
2017
Q2
$23.2M Buy
179,000
+18,000
+11% +$2.21M 1.14% 16
2017
Q1
$20M Sell
161,000
-14,000
-8% -$1.68M 1.02% 19
2016
Q4
$20.3M Sell
175,000
-47,000
-21% -$5.23M 1.09% 12
2016
Q3
$23.2M Buy
222,000
+7,000
+3% +$758K 1.23% 10
2016
Q2
$21.2M Buy
215,000
+20,000
+10% +$2.07M 1.16% 15
2016
Q1
$19.5M Buy
195,000
+12,000
+7% +$1.24M 1.09% 12
2015
Q4
$21.9M Buy
183,000
+4,500
+3% +$521K 1.2% 6
2015
Q3
$19.3M Buy
178,500
+15,000
+9% +$1.86M 1.1% 5
2015
Q2
$18.9M Buy
163,500
+16,500
+11% +$1.89M 0.99% 10
2015
Q1
$16.9M Buy
147,000
+14,000
+11% +$1.67M 0.87% 15
2014
Q4
$14.9M Hold
133,000
0.8% 19
2014
Q3
$12.6M Buy
+133,000
New +$12M 0.69% 35

Other funds holding CELG

EULAV Asset Management's CELG Position: Q2 2019 in Review

EULAV Asset Management sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 245,000 shares — an estimated $23M sold.

EULAV Asset Management first reported a position in CELG in Q3 2014 and held it in 19 quarters. The position peaked at $26.8M in Q3 2018. 1,288 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

  • EULAV Asset Management reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
  • EULAV Asset Management sold 245,000 Celgene Corp shares in Q2 2019, an estimated $23M.
  • EULAV Asset Management first reported a position in Celgene Corp in Q3 2014 and held it in 19 quarters.
  • EULAV Asset Management's Celgene Corp position peaked at $26.8M in Q3 2018.
  • 1,288 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on EULAV Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.